Single Cell RNA Sequencing for Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug screening methods using bulk RNA sequencing fail to account for cellular heterogeneity in tumors, leading to variable drug efficacy and resistance, resulting in ineffective treatments and high costs in clinical trials.
Innovation Solution
Implementing single-cell RNA sequencing (scRNA-seq) for drug screening and repurposing by culturing cell populations, exposing them to defined drug concentrations and times, generating single-cell libraries, and performing bioinformatic analysis to identify differentially expressed genes and pathways, which can reveal resistant subgroups and effective drug targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If bulk RNA sequencing is used for drug screening, then the screening process is simple and cost-effective, but cellular heterogeneity cannot be detected leading to inaccurate drug efficacy assessment
Solution Approach 1:
The patent segments the bulk tissue sample into individual single cells for sequencing. By isolating and sequencing RNA from individual cells rather than bulk tissue, the method reveals cellular heterogeneity and identifies distinct cell subpopulations with different drug responses, thereby improving measurement precision without requiring overly complex multi-omics approaches
Solution Approach 2:
The patent transitions from bulk RNA sequencing (averaging across all cells) to single-cell RNA sequencing (resolving individual cell dimensions). This dimensional shift from population-level to cell-level analysis enables detection of rare cell subpopulations and heterogeneous drug responses that were previously concealed in bulk measurements
2Reliability
If single-cell RNA sequencing is implemented for drug screening, then cellular heterogeneity and resistant subgroups can be identified, but the screening cost and complexity increase
Solution Approach 1:
The patent performs preliminary single-cell RNA sequencing during preclinical drug screening to identify resistant cell subpopulations and predict clinical treatment failure before expensive clinical trials begin. This preliminary action filters out promising drugs that would fail in clinical settings, improving reliability while containing costs by preventing later-stage failures
Solution Approach 2:
The patent uses single-cell RNA sequencing to provide feedback on drug responses at the individual cell level, identifying which cell subpopulations respond to treatment and which remain resistant. This feedback mechanism enables refinement of drug candidates and combination strategies based on actual cellular responses rather than bulk averages, improving reliability of drug selection
3Loss of time
If bulk drug screening methods are used, then time and resources are saved in preclinical stages, but drug efficacy is lost in clinical trials due to tumor heterogeneity
Solution Approach 1:
The patent performs single-cell RNA sequencing during preclinical drug screening to preliminarily assess drug efficacy across different cell subpopulations. This preliminary action identifies drugs that would fail in clinical trials due to heterogeneity, preventing wasted time and resources on translating ineffective drugs from preclinical to clinical stages
Solution Approach 2:
The patent dynamically tracks changes in cell subpopulation composition and gene expression in response to drug treatment using time-series single-cell RNA sequencing. This dynamic analysis reveals how tumors adapt to treatment and which drugs maintain efficacy against evolving cell populations, improving prediction of clinical outcomes and reducing translation failure
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention refers to scRNA-seq for high throughput drug screening and repurposing with primary cells or cell lines. It refers to a method for assaying a cell-based drug screening comprising the steps of: culturing a cell population in a culturing environment; exposing the cell population to drug substances, wherein defined monitoring points in time and concentration of the drug substances are set; generating a single cell library after exposure to drug substances; performing single cell RNA sequencing of the single cell libraries on a plurality of genes of the individually sorted cells from the cell library; and performing bioinformatic analysis to identify differentially expressed genes. Also, it refers to the use of a method for assaying a cell-based drug screening, wherein differentially expressed genes are potential marker genes and are used to screen drugs for cancers.